DOI QR코드

DOI QR Code

Tissue Expression, Serum and Salivary Levels of IL-10 in Patients with Head and Neck Squamous Cell Carcinoma

  • Hamzavi, Marzieh (Department of Oral and Maxillofacial Pathology, Shiraz University of Medical Sciences) ;
  • Tadbir, Azadeh Andisheh (Department of Oral and Maxillofacial Pathology, Shiraz University of Medical Sciences) ;
  • Rezvani, Gita (Department of Oral and Maxillofacial Pathology, Shiraz University of Medical Sciences) ;
  • Ashraf, Mohammad Javad (Department of Pathology, School of Medicine, Shiraz University of Medical Sciences) ;
  • Fattahi, Mohammad Javad (Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences) ;
  • Khademi, Bijan (Department of Otolaryngology, Khalili Hospital, Shiraz University of Medical Sciences) ;
  • Sardari, Yasaman (Department of Oral and Maxillofacial Pathology, Shiraz University of Medical Sciences) ;
  • Jeirudi, Naghmeh (School of Dentistry, Shiraz University of Medical Sciences)
  • 발행 : 2013.03.30

초록

Background: Head and neck SCC is a common cancer related to various factors. IL-10, a pleiotropic cytokine produced by macrophages, T-helper-2 cells, and B lymphocytes, is thought to play a potential pathogenetic or therapeutic role in a number of human conditions, such as inflammation, autoimmunity and cancer. The present study was designed to evaluate the relation between tissue expression, serum and salivary levels of IL-10 in head and neck squamous cell carcinomas (HNSCCs) and their correlation with clinicopathologic features. Materials and Methods: Samples were collected from 30 patients with HNSCCs and 24 healthy volunteers. IHC analysis was used to examine the tissue expression and ELISA was employed to measure serum and salivary levels. Results: Our study showed tissue expression of IL-10 to be significantily higher in patients (P: 0.001), but there was no relation between tissue expression, serum and salivary levels of the marker (P>0.05). Also except for a positive correlation between tissue expression of IL-10 and stage (P: 0.044), there was no relation between this marker and clinicopathologic features. There was no correlation between serum and salivary levels in either patients or controls. Conclusions: It seems there is no correlation between level of IL-10 in serum and saliva and this marker in saliva and serum does not reflect tissue expression.

참고문헌

  1. Alhamarneh O, Agada F, Madden L, et al (2010). Serum IL-10 and Circulating CD4+CD25inch regulatory T cell numvers aspredictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck, 10, 415-23.
  2. Asadullah S, Sterry W, Volk HD (2003). Interleukin-10 Therapy-Review of a new Approch. Pharmacol Rev, 55, 241-69. https://doi.org/10.1124/pr.55.2.4
  3. Berman RM, Suzuki T, Tahara H, et al (1996). Systemic administration of cellular IL-10 induces an effective, specific c, and long-lived immune response against established tymors in mice. J Immunol, 157, 231-8.
  4. Berzofsky JA, Terabe M (2009). The contrasing roles of NKT cells in tumor immunity. Curr Mol Med, 9, 667-72. https://doi.org/10.2174/156652409788970706
  5. Brooks M, Wang J, Li Y, et al (2008). Salivary protein factors are elevated in breast cancer patients. Nip Publish Access Author Manuscript, 1, 75-378.
  6. Cervenak L, Morbidelli L, Donati D, et al (2000). Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by Interleukin-10. Blood, 96, 2568-73.
  7. Chandler S, Rassekh C, Roadman S, et al (2002). Immunohistochemical localization of Interleukin-10 in human oral and pharyngeal carcinoma. Laryngoscope, 112, 808-15 https://doi.org/10.1097/00005537-200205000-00008
  8. DiLillo DJ, Matsushita T, Tedder TF (2010). B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann NY Acad Sci, 1183, 38-57. https://doi.org/10.1111/j.1749-6632.2009.05137.x
  9. Fujieda SH, Sunaga H, Tsuzuki H, et al (1999). IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Letter, 136, 1-9. https://doi.org/10.1016/S0304-3835(98)00281-X
  10. Hoffmann TK, Sonkoly E, Homey B (2007). Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck, 29, 472-8. https://doi.org/10.1002/hed.20533
  11. Lathers DM, Young MR (2004). Increased aberrance of cytokine expression in plasma of patient with more advanced squamous cell carcinoma of the head and neck. Cytokine, 25, 220-8. https://doi.org/10.1016/j.cyto.2003.11.005
  12. Linkov F, Lisovich A, Yurkovetsky Z (2007). Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev, 16, 102-7. https://doi.org/10.1158/1055-9965.EPI-06-0602
  13. Liu J, Song B, Wang JL, et al (2011). Polymorphisms of Interleukin-10 promoter are not associated with prognosis of advanced gastric cancer. World J Gastroenterol, 17, 1362-7 https://doi.org/10.3748/wjg.v17.i10.1362
  14. Nelson EL, Wenzel LB, Osann K, et al (2008). Stress, immunity and cervical cancer: biobehavioral outcomes of a randomized clinical trial. Clin Cancer Res, 14, 2111-8. https://doi.org/10.1158/1078-0432.CCR-07-1632
  15. Sabat R, Grutz G, Warszawska K, et al (2010). Biology of interleukin-10. Cytokine Growth factor REV, 21, 331-44. https://doi.org/10.1016/j.cytogfr.2010.09.002
  16. Shang ZJ, Li JR, Li ZB (2007). Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma. J Oral Maxillofact Surg, 65, 17-21. https://doi.org/10.1016/S0278-2391(07)00492-2
  17. Sparano A, Lathers DM, Achille N, et al (2004). Modulation of TH1 and TH2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg, 131, 573-6. https://doi.org/10.1016/j.otohns.2004.03.016
  18. Stearns ME, Rhim J, Wang M (1999). Interleukin-10(IL-10) inhibition of primary human prostate cellinduced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res, 5, 189-96.
  19. Teles RP, Likhari V, Socransky SS, et al (2009). Salivary cytokine levels in chronic periodontitis and periodomtally healthy subjects. A cross-sectional study. J Periodontal Res, 44, 411-7. https://doi.org/10.1111/j.1600-0765.2008.01119.x
  20. Toiyama Y, Miki C, Inoue Y, et al (2010). Loss of tissue expression of IL-10 promotes the disease progression of colorectal carcinoma. Surg Today, 46, 46-53.
  21. Wozniak KL, Arribas A, Leigh JE, et al (2002). Inhibitory effects of whole and parotid saliva on immunomodulators. Oral Microbiol Immunol, 17, 100-7. https://doi.org/10.1046/j.0902-0055.2001.00101.x
  22. Zheng LM, Ojcius DM, Garaud F, et al (1996). Interleukin-10 inhibits tumor metastasis through an NK cell dependent mechanism. J Exp Med, 184, 579-84. https://doi.org/10.1084/jem.184.2.579

피인용 문헌

  1. Association of Serum and Salivary Tumor Necrosis Factor-α with Histological Grading in Oral Cancer and its Role in Differentiating Premalignant and Malignant Oral Disease vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7141
  2. Associations among Inflammatory Biomarkers in the Circulating, Plasmatic, Salivary and Intraluminal Anatomical Compartments in Apparently Healthy Preschool Children from the Western Highlands of Guatemala vol.10, pp.6, 2015, https://doi.org/10.1371/journal.pone.0129158
  3. Evaluation of salivary level of IL-10 in patients with oral lichen planus, a preliminary investigation vol.26, pp.3, 2017, https://doi.org/10.1007/s00580-017-2415-5
  4. Mediators of Inflammation – A Potential Source of Biomarkers in Oral Squamous Cell Carcinoma vol.2018, pp.2314-7156, 2018, https://doi.org/10.1155/2018/1061780